Asia Pacific Liver Disease Diagnostics Market By End User, By Diagnosis Technique, By Country, Industry Analysis and Forecast, 2020 - 2026

The Asia Pacific Liver Disease Diagnostics Market is expected to witness market growth of 7.9% CAGR during the forecast period (2020-2026).

The market in the Asia Pacific is projected to rise significantly during the forecast period. The growing geriatric population and awareness of regular check-ups are contributing to the growth of the liver disease diagnostics market in this country. In addition, it is projected that the regulatory acceptance of emerging technology that can be incorporated with imaging systems is expected to fuel regional growth. For example, in August 2018, LiverMultiScan obtained approval from Therapeutic Goods Administration (TGA) to treat patients with highly prevalent diseases in Australia such as NAFLD and NASH.

An unhealthy diet, high-stress levels, and unorganized lifestyle patterns are the main drivers of the liver disease treatment market. Overweight and obesity rates in developing countries have increased dramatically, raising the chances of liver disease. In addition, increased alcohol consumption has fueled an increase in fatal liver disease. These factors also increased incidences of liver disease, which will fuel the growth of the liver disease treatment market in the future. Different strategies for the development of emerging technologies to advance patient care are being applied by key players.

Aging is a condition in which a person is gradually losing the ability to maintain homeostasis due to structural alteration or dysfunction. Aging is a major risk factor for the majority of chronic diseases. Aging has been shown not only to increase the vulnerability of acute liver injury but also to increase the susceptibility of fibrotic reactions. Aging is associated with the severity and poor prognosis of various diseases of the liver, including non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis C, and liver transplantation.

Structural dysfunction or modification due to aging primarily contributes to diseases of the liver. According to the National Institute of Aging, the geriatric population is expected to grow by 86% by 2050. Increased rates of the geriatric population have resulted in an increase in the incidence of liver disease, which has further increased the demand for the liver disease treatment market.

Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited

Scope of the Study

Market Segmentation:

By End User

• Hospitals, Laboratories and Other End Users

By Diagnosis Technique

• Imaging
• Biopsy
• Endoscopy
• Laboratory tests and
• Other Diagnosis Techniques

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Boston Scientific Corporation
• Siemens AG (Siemens Healthineers)
• Bayer AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Pfizer, Inc.
• Randox laboratories limited

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free